Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 29 Dec 2015 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Tata India Pharma & Healthcare Fund |
|---|---|
| 29 Dec 2015 | ₹100.00 |
| 17 Nov 2016 | ₹89.59 |
| 07 Oct 2017 | ₹87.59 |
| 27 Aug 2018 | ₹99.02 |
| 17 Jul 2019 | ₹94.57 |
| 05 Jun 2020 | ₹121.91 |
| 25 Apr 2021 | ₹172.83 |
| 14 Mar 2022 | ₹186.63 |
| 01 Feb 2023 | ₹181.26 |
| 22 Dec 2023 | ₹249.70 |
| 10 Nov 2024 | ₹349.64 |
| 30 Sep 2025 | ₹348.71 |
| 20 Aug 2026 | ₹383.57 |
| Metric | Tata · Direct · IDCW NAV ₹38.49 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| +6.11% | +5.11% | |
| +19.11% | +13.02% | |
| +14.75% | +11.14% | |
| +14.77% | +12.26% | |
| +13.46% | +11.82% | |
| +17.92% | — | |
| +18.14% | +14.62% | |
| +18.81% | +12.95% | |
| +14.05% | +13.24% | |
| Risk | ||
| 13.36% | 15.88% | |
| 0.94 | 0.35 | |
| 1.34 | 0.47 | |
| -19.84% | -25.18% | |
| Nifty 500 | — | |
| +8.43% | +1.40% | |
| 0.80 | 0.98 | |
| 112.0% | 101.5% | |
| 72.8% | 97.0% | |
| 1.00% | 1.14% | |
| ₹1,541Cr | ₹1,162Cr | |
| 0.25% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 27% | 45% | |
| Rajat Srivastava · 1.9y | — | |
| 29 Dec 2015 | — | |
| 34 | — | |
| 52.0% | — | |
| 2.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.